In Vivo CAR-T Landscape Survey Update

Research evidence excerpt

In Vivo CAR-T Landscape Survey Update

CMA CD3 LVV Phase 1 NCT07075185 Multiple myeloma

LVIVO-TaVec100 CD19xCD20 CD3 LVV Phase 1 NCT07002112 R/R NHL, R/R CLL

Legend Biotech Somerset, NJ LEGN LVIVO-TaVec200 GPRC5D CD3 LVV Phase 1 NCT07294625 Multiple myeloma

LVIVO-TaVec400 BCMA CD3 LVV Phase 1 NCT07399444 Multiple myeloma

Oricell Therapeutics Shanghai, China Private OriV508 CD19xBCMA NA LVV Phase 1 NCT07101705 Multiple myeloma & NHL

LV009 CD19 CD7 LVV Phase 1 NCT07284927, NCT07312630 CD19+ heme-malignancies

PersonGen BioTherapeutics Suzhou, China Private PG011 CD19xPD1 CD7 LVV Preclinical

PG016 NA CD7 LVV Preclinical

NA NA NA NA Phase 1 NCT07239323 R/R heme-malignancies Precision Biotech Chongqing, China Private

NA NA CD5 NA Phase 1 NCT06909474 R/R heme-malignancies

Sana Biotechnology Seattle, WA SANA SG293 CD19 CD8 LVV Preclinical

UB-VV500 Undisclosed CD3 LVV Preclinical

Umoja Biopharma Private UB-VV300/310 CD20 CD3 LVV Preclinical

Seattle, WA UB-VV200 Adapter (combo) CD3 LVV Preclinical

Umoja/Abbvie Private/ABBV UB-VV111 CD19 CD3 LVV Phase 1 NCT06528301 R/R LBCL, R/R CLL

Umoja/IASO Private UB-VV400/410 CD22 CD3 LVV Phase 1 NCT06743503 R/R NHL

Vivacta/Grit Bio Shanghai, China Private GT860 NA NA LVV Preclinical

Vyriad Rochester, MN Private VY169 BCMA CD3 LVV Preclinical

Source: Wells Fargo Securities, LLC, company presentations

AIHA: Autoimmune Hemolytic Anemia; ANCA-AAV: Anti neutrophil cytoplasmic antibody associated vasculitis; ASS: Antisynthetase Syndrome; DM: Dermatomyositis; IIM: Idiopathic Inflammatory

Myopathy; ITP: Immune Thrombocytopenia; LN: Lupus Nephritis; MN: Membranous Nephropathy; NM: Necrotizing Myopathy; PM: Polymyositis; SLE: Systemic lupus erythematosus, SS: Sjogren's

syndrome; SSc: Systemic Scleroderma

Equity Research | 3